Topic: disease awareness

September 19th, 2014

Call to Protect Public Health by Bolstering the World’s Defense Against Antimicrobial Resistance

by Adrian Thomas M.D., Vice President, Global Market Access & Commercial Strategy Operations and Head, Global Public Health at Janssen

Early in my career in Australia’s Flying Doctor Service, I had the privilege of providing emergency care to the rural poor.  In many cases, I was able to give my patients innovative treatments that cured their ailments and improved their health and lives overall.  The feelings I experienced from helping those vulnerable patients stays with me today and continues to drive me in my current role overseeing our global health portfolio of products and services for diseases of high public health impact and working with committed leaders advancing our technologies including those directed against HIV, tuberculosis, and Ebola.

Providing patients with effective treatments is the goal of every healthcare professional, scientific researcher, developer and manufacturer of new treatments and therapies.  When those treatments and therapies don’t exist, there is nothing harder than looking into the eyes of your patient and their loved ones and telling them there are no options.  It is their stories that compel us to do more to meet their needs by working together to bring forward new therapies.

The recent Ebola crisis and the rise in drug-resistant bacteria have forced our attention to the inadequacy of our therapeutic arsenals to address these major public health threats. 

Read More

August 4th, 2014

Education about Brain Disorders Benefits Us All

By Vicki Mabrey, Guest Contributor to JNJ Blog

Editor’s Note: Emmy-award winning journalist Vicki Mabrey is the host of Healthy Minds, a new digital news program about brain health from Janssen Research & Development, LLC, a Johnson & Johnson Company. 


Recently, it was my pleasure to learn more about the brain and disorders of the brain when I interviewed Janssen’s Global Therapeutic Area Head for Neuroscience, Dr. Husseini Manji. Dr. Manji shared his knowledge with me for the new Healthy Minds video series, which is launching this week on the Johnson & Johnson You Tube channel. It will cover general brain health, bipolar disorder, major depressive disorder, Alzheimer’s disease and schizophrenia. Working on the Healthy Minds series helped me to better understand the complexities of the brain and gain insights into diseases we hear about every day because our mothers, fathers, sons, daughters, and neighbors are suffering from them.


Throughout the world, about 450 million people suffer from a brain disorder, and in the US about one in four adults suffer from a diagnosable mental illness. That calculates to almost 60 million people.  Despite the prevalence and impact of these illnesses, nearly 60 percent of those affected do not consult medical professionals for treatment.

Read More

June 25th, 2014

Tracking Our Citizenship & Sustainability Journey

By Shaun Mickus, Director, Corporate Citizenship, Johnson & Johnson

Citizenship-Sustainability Trading-Card_Blogpost

Perhaps one of the most defining moments in the history of Johnson & Johnson occurred more than 70 years ago when General Robert Wood Johnson, son of one of the Company’s co-founders, wrote Our Credo, outlining our responsibilities to all stakeholders and to the communities in which we live and work. It was 1943, a time when very few even understood or appreciated the importance of corporate responsibility in serving the needs of many groups and contributing to the long-term vitality of a business. This 308-word document has stood the test of time and continues to serve as the guide we try to live by every day. And, it is the essence of what citizenship and sustainability means for Johnson & Johnson.

We see our citizenship and sustainability as more than our social, environmental and economic performance. It is who we are and how we act. Our new Citizenship & Sustainability Annual Report gives us the opportunity to share with our diverse stakeholders the ways we are:

  • Working and partnering with others to advance human health and well-being,
  • Helping to safeguard the planet, and
  • Leading a dynamic and growing business responsibly.

Read More

May 23rd, 2014

An Ethicon Donation That Improves Access to Much-needed Surgery

By Denis Robson, Director, African Affairs, Johnson & Johnson Medical UK

Today marks the first anniversary of the International Day to End Obstetric Fistula, announced last year by the United Nations. And while there are many “days” to help the global health and development communities raise awareness about pressing challenges, fistula holds a special significance.

Two decades ago, a surgeon in Ethiopia, Dr. Catherine Hamlin, made an appeal for absorbable sutures for use in surgeries to repair obstetric fistula, a debilitating childbirth injury that causes uncontrollable leaking of feces or urine. Women suffering from fistula are often shunned by their husbands and communities, and forced to live in isolation.

Sheila Rinning, who worked in the export department in Edinburgh, Scotland for Ethicon, a Johnson & Johnson subsidiary, responded to Dr. Hamlin’s call. Little did she know that this would be the beginning of a partnership that has lasted nearly two decades, and led to thousands of life-saving surgeries for women in need.

Following Dr. Hamlin’s appeal, Sheila devoted time each month to prepare four separate packages containing absorbable and silk sutures for use in fistula surgeries. Why separate? The postal service couldn’t reliably deliver the package to their destination in Ethiopia – so four packages were sent separately, with the hope that at least one would make it to the destination in Addis Ababa.

Read More

May 20th, 2014

The Eyes Have It: Exposure to UV Rays a Silent Threat to Vision

By Millicent Knight, OD, Head of Professional Affairs, Johnson & Johnson Vision Care, North America

May is Healthy Vision Month, a perfect time to ask: Are we taking the proper precautions to protect our eyes?  Unfortunately, the answer is no. Eyes may be windows to the soul, but they are also windows for harmful ultraviolet (UV) radiation, which can cause silent, long-term damage on our vision that may occur decades later.

This issue is particularly timely with summer around the corner—a season in which it’s almost intuitive to lather on the sunscreen before we head to the beach.  While most Americans understand the link between UV radiation and skin cancer, many are less aware of the connection between UV radiation and eye damage. Yet the truth is that harmful UV rays are not just bad for skin; they also can inflict significant eye damage over time. Worldwide some 12 to 15 million people become blind from cataracts annually, of which up to 20% may be caused or enhanced by sun exposure according to estimates from The World Health Organization1. UV rays also have been linked to other ocular conditions.

What’s more, UV rays can cause short-term conditions such as photokeratitis (a corneal inflammation) and photoconjunctivitis (an inflammation of the conjunctiva under the eyelid).

Read More

May 15th, 2014

Partnering to Protect Women from HIV

Editor’s Note: Last week the Janssen Pharmaceutical Companies of Johnson & Johnson, expanded its collaboration with the International Partnership for Microbicides (IPM) granting IPM exclusive worldwide rights to develop, manufacture, and market sexual and reproductive health products containing Janssen’s antiretroviral drug dapivirine. This is the latest innovative public-private partnership from the newly established Janssen Global Public Health group and a significant contribution to Johnson & Johnson’s wider efforts to improve public health – and the health of women and girls – worldwide.

Though we’ve made great strides in developing new medicines for HIV, treatment alone is not the solution. Women and girls, particularly in sub-Saharan Africa where the HIV epidemic has hit hardest, are particularly vulnerable to infection. In fact, HIV prevalence among young women in sub-Saharan Africa is more than twice as high as that of young men throughout the region. These women and girls need new prevention tools to empower themselves to protect their health.

Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Janssen, co-authored an Op-Ed appearing on Global Post with Zeda Rosenberg, Chief Executive Officer, IPM discussing this significant effort and the importance of these types of public-private partnerships benefitting women and girls.

Read More

May 5th, 2014

Supporting World Asthma Day

Editor’s Note: In recognition of World Asthma Day, which is Tuesday, May 6, Janssen pledges its continued focus to advance disease understanding, medicines and solutions for people living with asthma worldwide.

Janssen Research & Development proudly joins the Global Initiative for Asthma (GINA) in support of World Asthma Day, an annual event intended to improve asthma awareness and care for this difficult-to-treat, and potentially, life-threatening disease that affects more than 300 million people worldwide.

Janssen continues to advance the scientific understanding of the condition, and work towards the discovery, development and ultimately, the delivery of treatments for patients living with severe asthma. We are evaluating the heterogeneity of patients living with pulmonary disease to understand the underlying disease biology, seeking to provide better personalized treatment options no matter what the severity of the symptoms entails.

Our goal, together with internal and external collaboration partners, is to help people live a vibrant and healthy life, free from the debilitating symptoms associated with this life-altering disease.

You can learn more about this disease and our efforts – and share the information with others – in our latest infographic.

Read More

April 29th, 2014

Championing Collaboration to Tackle Unmet Public Health Needs

By Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson and Worldwide Chairman, Janssen

One of my lifelong goals was to change the treatment landscape for tuberculosis, especially for patients affected by multi-drug resistant tuberculosis (MDR-TB). MDR-TB is a particularly deadly and hard-to-treat form of TB. It kills many people every year, especially those already affected by HIV and it threatens the progress made in the fight against TB globally.

Although there is broad consensus that it is imperative to stop TB, resistance to most TB treatments is largely a manmade challenge. Improper use of TB antibiotics due to inadequate drug supply, limited diagnostics, poor prescribing practices, vulnerable patient populations and limited data are just a few of the challenges fueling the cycle of resistance.

National TB programs, dedicated advocates, scientists and industry each have something to offer in the fight against MDR-TB, but collaboration among all of us is crucial. At Janssen, we are able to offer new treatment options and support clinical trials, and through partnerships with diverse stakeholders we can also help ensure access and appropriate use in this complex treatment environment.

That’s why we are pleased to announce a collaboration with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF) to help reach patients in more than 130 low- and middle-income countries outside of the United States.

Read More

February 25th, 2014

Honoring Rare Disease Day: Spotlight on Multicentric Castleman’s Disease

by Joanne Vanak, RN, MSN; Senior Director of Medical Affairs Scientific Advocacy, Janssen Scientific Affairs, LLC

Rare Disease Day

Imagine living with a disease so rare it’s hard to get the proper diagnosis. Picture life as a patient with a condition so unique you can barely find a physician with the experience to treat it. Unfortunately, for the nearly 25 to 30 million Americans who suffer from one of the approximately 6,800 rare diseases recognized in the United States,[1] this uncertainty is a reality. And it’s one of the primary reasons Johnson & Johnson and Janssen remain committed to uncovering treatment options for those facing unmet medical needs.

In the United States, a disease is considered rare if it affects fewer than 200,000 Americans.[1] Some rare diseases affect only a fraction of that. For example, in the case of a disease called Multicentric Castleman’s disease, or MCD, the patient numbers are so low that it’s difficult to get an accurate estimate of the number of people impacted. However, based on approximate calculations, experts believe there are fewer than 2,000 Americans with this condition.[2]*

So what is MCD? It is a disorder in which lymphocytes, a certain type of white blood cells, are over-produced, causing enlargement of lymph nodes or other internal organs containing lymphoid tissue.

Read More

September 18th, 2013

Continuing to Lead by Example – Johnson & Johnson Recognized for Global Cancer Prevention and Support in the Workplace

by Fik Isaac, MD, Vice President Global Health Services and Chief Medical Officer, Wellness & Prevention, Inc., a Johnson & Johnson Company

Back in 2001, Former President George H. W. Bush, the 41st President of the United States, asked a gentleman named Robert Ingram (CEO of Glaxo Wellcome at the time) to chair the CEO Roundtable on Cancer in support of an initiative known as the C-Change.  This national forum brought together key leaders from business, government and academia, who shared the common goal to eliminate cancer.  Specifically, Mr. Bush asked Mr. Ingram to form a separate organization of action-oriented chief executive officers that would “do something” about cancer prevention, diagnosis and treatment for their own families, as well as their corporate families.  And, well, the rest is history.

Today, the CEO Roundtable on Cancer is a 501(c)(3) nonprofit organization that remains committed to fulfilling Former President Bush’s challenge to be “bold and venturesome” in considering the health of employees and the war against cancer.  This rings true in each of the organization’s three key categories: risk reduction, early detection and quality care.  And more than four million employees and family members are benefiting from the vision and leadership of nearly 150 employers who’ve chosen to become Gold Standard accredited.

Read More